Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTOR | P42345 | 20/20 | 0.67 |
| ▸ | PIK3CA | P42336 | 13/20 | 0.67 |
| ▸ | PIK3CG | P48736 | 5/20 | 0.67 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.63 |
| ▸ | PIK3R1 | P27986 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13718348 | 0.89 | MTOR (0.57) | MTORPIK3CAPIK3CGPIK3CD | |
| SCHEMBL13828916 | 0.87 | MTOR (0.76) | MTORPIK3CAPIK3CGPIK3CD | |
| SCHEMBL13828706 | 0.85 | MTOR (0.65) | MTORPIK3CAPIK3CGPIK3CD | |
| SCHEMBL13828975 | 0.84 | MTOR (0.78) | MTORPIK3CAPIK3CGPIK3CD | |
| SCHEMBL13828566 | 0.82 | MTOR (0.76) | MTORPIK3CAPIK3CGPIK3CD | |
| SCHEMBL32474 | 0.81 | PIK3CA (1.00) | MTORPIK3CAPIK3CGPIK3R1 | |
| SCHEMBL13828664 | 0.80 | MTOR (0.70) | MTORPIK3CAPIK3CGPIK3R1 | |
| SCHEMBL13828923 | 0.79 | MTOR (0.70) | MTORPIK3CAPIK3CG | |
| SCHEMBL3989822 | 0.78 | MTOR (0.68) | MTORPIK3CAPIK3CGPIK3CDPIK3R1 | |
| SCHEMBL3989299 | 0.78 | MTOR (0.64) | MTORPIK3CAPIK3CGPIK3CDPIK3R1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120288492-A1 | NOVEL PYRIMIDINE COMPOUNDS AS mTOR AND PI3K INHIBITORS | DCB-USA LLC (US) | 2012-11-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120288492-A1 | NOVEL PYRIMIDINE COMPOUNDS AS mTOR AND PI3K INHIBITORS | MTOR, PIK3CA, TYMS | MTOR 1/4885PIK3CA 2/4885PIK3CG 9/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.